Put companies on watchlist
Cannovum Cannabis AG
ISIN: DE000A2LQU21
WKN: A2LQU2
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Cannovum Cannabis AG · ISIN: DE000A2LQU21 · EQS - Company News (50 News)
Country: Germany · Primary market: Germany · EQS NID: 1631357
12 May 2023 09:28AM

Cannovum Cannabis AG signs agreement together with to establish cultivation alliance


EQS-News: Cannovum Cannabis AG / Key word(s): Investment/Expansion
Cannovum Cannabis AG signs agreement together with to establish cultivation alliance

12.05.2023 / 09:28 CET/CEST
The issuer is solely responsible for the content of this announcement.


Cannovum Cannabis AG Signs Agreement Together With Co-Founders to Establish Germany’s First Cultivation Alliance For Cannabis Anbau-Allianz GmbH

Cannovum Cannabis AG (stock exchanges Frankfurt, Xetra, Düsseldorf, Munich, Hamburg, Berlin, Tradegate, gettex: ISIN DE000A2LQU21) signs together with the co-founders Tim Spieker and Elimar Moormann the contract for the foundation of the Cultivation Alliance for Germany GmbH, Anbau-Allianz für Deutschland.

Following the launch of Anbau-Allianz für Deutschland in February 2023, the contract to establish Anbau-Allianz für Deutschland GmbH has now been signed. The founders of Anbau-Allianz GmbH include Tim Spieker and Elimar Moormann, co-founder of Horcantus GmbH. The Cultivation Alliance for Germany is managed by the operational managing directors Tim Spieker and Klaus Madzia, further managing directors are Pia Marten and Elimar Moormann. In the coming weeks, other high-ranking and well-known companies will become part of the Anbau-Allianz.

“We are excited to drive the availability of recreational cannabis in Germany with the Cultivation Alliance for Germany,” said managing director Tim Spieker. “In the coming months, we will focus on products and services that enable cannabis club operators to grow high-quality recreational cannabis.” The focus will be set on premium quality, legal security and ecologically sustainable cultivation. The Cultivation Alliance relies on and unifies best practice examples of German agriculture.

After the announcements of the German Health Minister Karl Lauterbach regarding the cannabis legalization in Germany, the Cultivation Alliance is an important step to strengthen producers and club operators. The Cultivation Alliance allows creating a network to connect experts from branches such as cultivation, technology, and distribution to encourage exchange within the cannabis industry. The goal is to actively shape the future of the cannabis legalization in a sustainable and ecologically valuable way and to provide high-quality and controlled cannabis products with the upcoming legalization.

 

Cannovum Cannabis AG CEO Pia Marten: “Our long experience in the field of medicinal cannabis is a crucial asset for the cultivation alliance. Especially in the coming weeks, the legislators will concretize the legal framework and with our know-how, we can significantly support Cannabis Club operators on the way to legal cultivation and legal dispensing.

 

 

Cantact::

Klaus Madzia

IR & PR

Cannovum Cannabis AG

Telefon: +49 30 3982 163 62

E-Mail: klaus.madzia@cannovum.com

 

 

Cannovum Cannabis AG is the first German fully licensed cannabis company,

that is listed on the stock exchange. The shares are traded on the stock exchanges of

Frankfurt, Xetra, Düsseldorf, Munich, Berlin, Hamburg and gettex. The

Cannovum Cannabis AG is ready for the legalization of cannabis and is well

prepared: for sales through pharmacies as well as through licensed specialty stores.

 

Through its subsidiary Cannovum Health eG, it is a fully licensed

pharmaceutical wholesaler, importer, and manufacturer of high-quality medicinal

cannabis products, with headquarters in Berlin. Already today, Cannovum Cannabis AG is a

market leader in the medical cannabis sector.

 

Currently, the company is active in the importation of high-quality cannabinoid precursors, medical-scientific education and nationwide distribution for a simplified and equitable access to cannabis-based therapies.

 

 

 

 



12.05.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Cannovum Cannabis AG
Rheinsberger Str. 76/77
10115 Berlin
Germany
Phone: +49 (0)30 3982 16360
E-mail: klaus.madzia@cannovum.com
Internet: www.cannovum.com
ISIN: DE000A2LQU21
WKN: A2LQU2
Listed: Regulated Unofficial Market in Berlin, Dusseldorf (Primärmarkt), Frankfurt, Hamburg, Munich
EQS News ID: 1631357

 
End of News EQS News Service

1631357  12.05.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1631357&application_name=news&site_id=boersengefluester_html

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.